The U.S. Food and Drug Administration has extended its review timeline for Exelixis' (EXEL) zanzalintinib-atezolizumab combination therapy, a potential treatment for previously treated metastatic colorectal cancer. The new action date is March 3, 2027, a three-month delay from the original December 3, 2026 deadline. This adjustment follows the submission of updated safety and efficacy data, which the agency classified as a major amendment to the pending application.
This is a delay rather than a rejection, but it carries more weight than a routine scheduling change. According to Exelixis' September 11 filing, the additional data was provided in response to an FDA information request. The company did not disclose the nature of the agency's query, nor did it indicate any new safety findings or a change in the approval criteria. This lack of detail has left investors to interpret the implications, contributing to a notable market reaction.
On Friday, shares of Exelixis dropped from $59.13 to $56.12, a decline of 5.09% based on closing prices. With approximately 247.8 million shares outstanding as of July 27, this move erased roughly $746 million in market capitalization, leaving the company valued at about $13.9 billion. The stock's decline reflects increased uncertainty surrounding the drug's approval prospects and the potential impact on Exelixis' future revenue stream.
Clinical Trial Results Under Scrutiny
The application is based on the STELLAR-303 phase 3 trial, which compared the combination of zanzalintinib and Roche's atezolizumab against regorafenib, a standard treatment. In the intention-to-treat population, the combination reduced the risk of death by 20%, with a hazard ratio of 0.80 (95% CI: 0.69-0.93, p=0.0045). This statistically significant overall survival benefit met one of the trial's two primary endpoints.
However, the second primary endpoint, which focused on patients without active liver metastases, was less conclusive. The hazard ratio was 0.83, but the 95% confidence interval (0.66-1.05) crossed 1, and the p-value was 0.1185, indicating the result was not statistically significant. Median overall survival in this subgroup was 15.9 months for the combination versus 12.7 months for regorafenib. These figures were disclosed in Exelixis' latest 10-Q filing, although the company's earlier update on STELLAR-303 had highlighted the positive full-population result.
Investor Sentiment and Financial Resilience
The mixed clinical data, combined with the FDA's request for additional information, has led investors to reassess the likelihood and timing of approval. The phrase "updated safety and efficacy data" warrants attention without being overinterpreted. While the full-population survival benefit is encouraging, the lack of statistical significance in the liver-metastases subgroup raises questions about the drug's overall risk-benefit profile.
Despite the regulatory setback, Exelixis' near-term financial position remains solid. The company's lead product, Cabometyx, generated $570.6 million in net product revenue in the second quarter, accounting for 99.6% of product sales and approximately 91% of total revenue. As of June 30, Exelixis held $1.384 billion in cash and marketable securities, and it produced $559.6 million in operating cash flow during the first half of the year. This financial strength provides a buffer to withstand a prolonged review process.
Strategic Importance of Zanzalintinib
The delay also underscores the strategic importance of zanzalintinib for Exelixis, which remains heavily reliant on Cabometyx. A successful approval would diversify the company's revenue base and reduce its concentration risk. Investors are not merely pricing in a three-month postponement of potential sales; they are adjusting their expectations for the probability and timing of a second major oncology product.
Bullish investors argue that additional review time could resolve the information request without affecting the eventual label or launch economics. Conversely, bears point to the added layer of safety, efficacy, or labeling uncertainty, especially given the missed statistical threshold in one primary population. Neither interpretation is definitively supported by Friday's announcement.
Looking Ahead
Between now and March 3, 2027, investors should monitor specific signals that could clarify the situation. These include any FDA-requested meetings or new filings, a more detailed presentation of the non-liver-metastases data, updates on management's launch preparations, and ultimately the breadth of any approved label. A recovery in Exelixis' stock price alone would not provide answers to these questions. The next durable move in the stock should be driven by what the amendment changes, not merely by the passage of time.
